ER7 Fundamental Analysis - ERAMET

Fundamental Rating

Taking everything into account, ER7 scores 2 out of 10 in our fundamental rating. ER7 was compared to 40 industry peers in the Metals & Mining industry. ER7 may be in some trouble as it scores bad on both profitability and health. ER7 does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

ER7 had negative earnings in the past year.

ER7 had a negative operating cash flow in the past year.

Of the past 5 years ER7 4 years were profitable.

ER7 had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -1.58%, ER7 is doing worse than 65.00% of the companies in the same industry.

ER7 has a Return On Equity of -9.29%. This is in the lower half of the industry: ER7 underperforms 75.00% of its industry peers.

The Return On Invested Capital of ER7 (0.80%) is worse than 67.50% of its industry peers.

The Average Return On Invested Capital over the past 3 years for ER7 is in line with the industry average of 7.89%.

The last Return On Invested Capital (0.80%) for ER7 is well below the 3 year average (7.29%), which needs to be investigated, but indicates that ER7 had better years and this may not be a problem.

		Industry Rank	Sector Rank
ROA	-1.58%
ROE	-9.29%
ROIC	0.8%

ROA(3y)4.1%

ROA(5y)1.33%

ROE(3y)16.44%

ROE(5y)-1.91%

ROIC(3y)7.29%

ROIC(5y)7.73%

1.3 Margins

In the last couple of years the Profit Margin of ER7 has declined.

The Operating Margin of ER7 (1.91%) is worse than 65.00% of its industry peers.

In the last couple of years the Operating Margin of ER7 has declined.

ER7's Gross Margin of 68.15% is amongst the best of the industry. ER7 outperforms 87.50% of its industry peers.

In the last couple of years the Gross Margin of ER7 has grown nicely.

		Industry Rank	Sector Rank
OM	1.91%
PM (TTM)	N/A
GM	68.15%

OM growth 3Y-46.5%

OM growth 5Y-18.83%

PM growth 3Y-61.12%

PM growth 5YN/A

GM growth 3Y-3.21%

GM growth 5Y23.96%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ER7 is destroying value.

ER7 has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, ER7 has more shares outstanding

Compared to 1 year ago, ER7 has an improved debt to assets ratio.

2.2 Solvency

ER7 has an Altman-Z score of 1.07. This is a bad value and indicates that ER7 is not financially healthy and even has some risk of bankruptcy.

ER7 has a worse Altman-Z score (1.07) than 70.00% of its industry peers.

ER7 has a Debt/Equity ratio of 2.03. This is a high value indicating a heavy dependency on external financing.

With a Debt to Equity ratio value of 2.03, ER7 is not doing good in the industry: 90.00% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	2.03
Debt/FCF	N/A
Altman-Z	1.07

ROIC/WACC0.09

WACC9.1%

2.3 Liquidity

ER7 has a Current Ratio of 1.54. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.

ER7 has a worse Current ratio (1.54) than 70.00% of its industry peers.

ER7 has a Quick Ratio of 1.06. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.

The Quick ratio of ER7 (1.06) is worse than 62.50% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.54
Quick Ratio	1.06

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ER7 have decreased strongly by -221.18% in the last year.

Measured over the past years, ER7 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -64.00% on average per year.

Looking at the last year, ER7 shows a decrease in Revenue. The Revenue has decreased by -6.91% in the last year.

The Revenue has been decreasing by -4.39% on average over the past years.

EPS 1Y (TTM)-221.18%

EPS 3Y-64%

EPS 5YN/A

EPS Q2Q%-268.75%

Revenue 1Y (TTM)-6.91%

Revenue growth 3Y-7.18%

Revenue growth 5Y-4.39%

Sales Q2Q%-3.31%

3.2 Future

Based on estimates for the next years, ER7 will show a very negative growth in Earnings Per Share. The EPS will decrease by -26.37% on average per year.

ER7 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.00% yearly.

EPS Next Y-109.87%

EPS Next 2Y-56.27%

EPS Next 3Y-26.37%

EPS Next 5YN/A

Revenue Next Year3.03%

Revenue Next 2Y7.1%

Revenue Next 3Y8%

Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ER7 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ER7. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as ER7.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	14.15

4.3 Compensation for Growth

ER7's earnings are expected to decrease with -26.37% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-56.27%

EPS Next 3Y-26.37%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ER7 has a Yearly Dividend Yield of 2.61%.

ER7's Dividend Yield is a higher than the industry average which is at 1.97.

Compared to an average S&P500 Dividend Yield of 1.87, ER7 pays a bit more dividend than the S&P500 average.

		Industry Rank	Sector Rank
Dividend Yield	2.61%

5.2 History

Dividend Growth(5Y)N/A

Div Incr Years0

Div Non Decr Years1

5.3 Sustainability

ER7 has negative earnings and hence a negative payout ratio. The dividend may be in danger.

DP-44.33%

EPS Next 2Y-56.27%

EPS Next 3Y-26.37%

More info and screens

Find the best dividend stocks

Show peers with best dividend

ERAMET

FRA:ER7 (12/16/2025, 7:00:00 PM)

48.58

-0.88 (-1.78%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryMetals & Mining

Earnings (Last)10-30 2025-10-30

Earnings (Next)02-17 2026-02-17/amc

Inst Owners15.59%

Inst Owner ChangeN/A

Ins Owners0.17%

Ins Owner ChangeN/A

Market Cap1.40B

Revenue(TTM)2.88B

Net Income(TTM)-97.00M

Analysts52.73

Price Target53.14 (9.39%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	2.61%

Yearly Dividend1.51

Dividend Growth(5Y)N/A

DP-44.33%

Div Incr Years0

Div Non Decr Years1

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)1.49%

PT rev (3m)-7.36%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)95.13%

EPS NY rev (3m)94.35%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-1.78%

Revenue NY rev (3m)-3.55%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.48
P/FCF	N/A
P/OCF	N/A
P/B	1.34
P/tB	2.59
EV/EBITDA	14.15

EPS(TTM)-3.44

EYN/A

EPS(NY)-1.86

Fwd EYN/A

FCF(TTM)-25.76

FCFYN/A

OCF(TTM)-4.59

OCFYN/A

SpS100.31

BVpS36.3

TBVpS18.78

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-1.58%
ROE	-9.29%
ROCE	1.16%
ROIC	0.8%
ROICexc	0.95%
ROICexgc	1.09%
OM	1.91%
PM (TTM)	N/A
GM	68.15%
FCFM	N/A

ROA(3y)4.1%

ROA(5y)1.33%

ROE(3y)16.44%

ROE(5y)-1.91%

ROIC(3y)7.29%

ROIC(5y)7.73%

ROICexc(3y)10.98%

ROICexc(5y)11.38%

ROICexgc(3y)12.91%

ROICexgc(5y)13.43%

ROCE(3y)10.76%

ROCE(5y)11.32%

ROICexgc growth 3Y-56.22%

ROICexgc growth 5Y-25.38%

ROICexc growth 3Y-55.33%

ROICexc growth 5Y-24.94%

OM growth 3Y-46.5%

OM growth 5Y-18.83%

PM growth 3Y-61.12%

PM growth 5YN/A

GM growth 3Y-3.21%

GM growth 5Y23.96%

F-Score2

Asset Turnover0.47

Health

		Industry Rank	Sector Rank
Debt/Equity	2.03
Debt/FCF	N/A
Debt/EBITDA	10.29
Cap/Depr	403.31%
Cap/Sales	21.11%
Interest Coverage	0.34
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.54
Quick Ratio	1.06
Altman-Z	1.07

F-Score2

WACC9.1%

ROIC/WACC0.09

Cap/Depr(3y)260.42%

Cap/Depr(5y)209.27%

Cap/Sales(3y)18.57%

Cap/Sales(5y)15.29%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-221.18%

EPS 3Y-64%

EPS 5YN/A

EPS Q2Q%-268.75%

EPS Next Y-109.87%

EPS Next 2Y-56.27%

EPS Next 3Y-26.37%

EPS Next 5YN/A

Revenue 1Y (TTM)-6.91%

Revenue growth 3Y-7.18%

Revenue growth 5Y-4.39%

Sales Q2Q%-3.31%

Revenue Next Year3.03%

Revenue Next 2Y7.1%

Revenue Next 3Y8%

Revenue Next 5YN/A

EBIT growth 1Y-51.75%

EBIT growth 3Y-50.34%

EBIT growth 5Y-22.39%

EBIT Next Year-12.75%

EBIT Next 3Y24.29%

EBIT Next 5YN/A

FCF growth 1Y-850%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-121.46%

OCF growth 3YN/A

OCF growth 5YN/A

ERAMET / ER7.DE FAQ

What is the fundamental rating for ER7 stock?

ChartMill assigns a fundamental rating of 2 / 10 to ER7.DE.

What is the valuation status for ER7 stock?

ChartMill assigns a valuation rating of 0 / 10 to ERAMET (ER7.DE). This can be considered as Overvalued.

What is the profitability of ER7 stock?

ERAMET (ER7.DE) has a profitability rating of 3 / 10.

How financially healthy is ERAMET?

The financial health rating of ERAMET (ER7.DE) is 1 / 10.

Can you provide the dividend sustainability for ER7 stock?

The dividend rating of ERAMET (ER7.DE) is 3 / 10 and the dividend payout ratio is -44.33%.

ERAMET (ER7.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens

ERAMET / ER7.DE FAQ

What is the fundamental rating for ER7 stock?

What is the valuation status for ER7 stock?

What is the profitability of ER7 stock?

How financially healthy is ERAMET?

Can you provide the dividend sustainability for ER7 stock?